...
首页> 外文期刊>Journal of the American College of Cardiology >Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
【24h】

Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

机译:非ST段抬高的急性冠脉综合征的高龄,抗血栓形成策略和出血:ACUITY(急性导管插入和紧急干预分类策略)试验的结果。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: This study sought to evaluate the impact of age on outcomes in patients with moderate- and high-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) enrolled in the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. BACKGROUND: Aging-associated changes in physiology and metabolism may alter the risk and benefit of therapeutic strategies from that observed in younger people. METHODS: We performed a pre-specified analysis of 30-day and 1-year outcomes in 4 age groups, overall and among those undergoing percutaneous coronary intervention (PCI). RESULTS: Of 13,819 patients in the ACUITY trial, 3,655 (26.4%) were <55 years of age, 3,940 (28.5%) were 55 to 64 years of age, 3,783 (27.4%) were 65 to 74 years of age, and 2,441 (17.7%) were > or =75 years of age. Older patients had more cardiovascular risk factors and had a higher acuity at presentation. Patients age > or =75 years treated with bivalirudin alone had similar ischemic outcomes, but significantly lower rates of bleeding compared with those treated with heparin and glycoprotein IIb/IIIa inhibitors overall and in the PCI subset. The number needed to treat with bivalirudin alone to avoid 1 major bleeding event was lower in this age group (23 overall and 16 for PCI-treated patients) than in any other. CONCLUSIONS: Ischemic and bleeding complications after NSTE-ACS increase with age. Although ischemic event rates are not statistically different with either bivalirudin alone or a heparin plus glycoprotein IIb/IIIa inhibitor, bleeding complications are significantly less frequent with bivalirudin alone. Because of the substantial risk of bleeding in patients age > or =75 years, the number needed to treat to avoid 1 major bleeding event using bivalirudin alone was the lowest in the elderly group, especially among those undergoing PCI.
机译:目的:本研究旨在评估年龄对参加ACUITY(急性导管插入和紧急干预分类策略)试验的中高危非ST段抬高急性冠状动脉综合征(NSTE-ACS)患者结局的影响。背景:与衰老相关的生理学和代谢变化可能会改变治疗策略的风险和益处,而这一点在年轻人中观察到。方法:我们对4个年龄段的总体和接受经皮冠状动脉介入治疗(PCI)的人群进行了30天和1年预后的预先分析。结果:在ACUITY试验的13,819名患者中,年龄<55岁的3,655名(26.4%),年龄55至64岁的3,940名(28.5%),年龄65-74岁的3,783名(27.4%)和2,441名(17.7%)为75岁或以上。年龄较大的患者有更多的心血管危险因素,并且呈现时的敏锐度更高。单独使用比伐卢定治疗的年龄大于或等于75岁的患者具有相似的缺血结局,但与总体上和在PCI子集中使用肝素和糖蛋白IIb / IIIa抑制剂治疗的患者相比,出血率显着降低。在这个年龄组中,仅用比伐卢定治疗以避免1次大出血事件所需的人数就比其他任何人都要低(总体为23,PCI治疗的患者为16)。结论:NSTE-ACS术后缺血和出血并发症随年龄增加而增加。尽管单独使用比伐卢定或使用肝素加糖蛋白IIb / IIIa抑制剂对缺血事件的发生率无统计学差异,但仅使用比伐卢定,出血并发症的发生率显着降低。由于年龄大于或等于75岁的患者存在大量出血的风险,因此在老年人组中,尤其是接受PCI的患者中,仅使用比伐卢定可以避免1次重大出血事件的治疗人数最低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号